Is MIST or TTRX more profitable?

Turn Therapeutics' return on equity of -230.84% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Milestone Pharmaceuticals N/A -288.33% -58.27% Turn Therapeutics N/A -230.84% -53.19%

Is RLMD or MIST more profitable?

Relmada Therapeutics' return on equity of -47.52% beat Milestone Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Relmada Therapeutics N/A -47.52% -43.97% Milestone Pharmaceuticals N/A -288.33% -58.27%

Milestone Pharmaceuticals (MIST) Competitors

$0.76 +0.05 (+6.73%)

Closing price 04:00 PM Eastern

Extended Trading

$0.75 -0.01 (-1.18%)

As of 05:03 PM Eastern

Compare

MIST vs. ENTA, TTRX, FENC, RLMD, and ACB

Should you buy Milestone Pharmaceuticals stock or one of its competitors? Milestone Pharmaceuticals's main competitors and comparable companies include Enanta Pharmaceuticals (ENTA), Turn Therapeutics (TTRX), Adherex Technologies (FENC), Relmada Therapeutics (RLMD), and Aurora Cannabis (ACB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Milestone Pharmaceuticals compare to Enanta Pharmaceuticals?

Enanta Pharmaceuticals (NASDAQ:ENTA) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Enanta Pharmaceuticals had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Enanta Pharmaceuticals and 0 mentions for Milestone Pharmaceuticals. Enanta Pharmaceuticals' average media sentiment score of 0.19 beat Milestone Pharmaceuticals' score of 0.00 indicating that Enanta Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Enanta Pharmaceuticals	Neutral
Milestone Pharmaceuticals	Neutral

Enanta Pharmaceuticals has a beta of 0.96, meaning that its stock price is 4% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 1.01, meaning that its stock price is 1% more volatile than the broader market.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Enanta Pharmaceuticals' net margin of -96.89%. Enanta Pharmaceuticals' return on equity of -61.84% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enanta Pharmaceuticals	-96.89%	-61.84%	-20.70%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

Milestone Pharmaceuticals has lower revenue, but higher earnings than Enanta Pharmaceuticals. Enanta Pharmaceuticals is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enanta Pharmaceuticals	$65.32M	5.39	-$81.89M	-$2.41	N/A
Milestone Pharmaceuticals	$1.55M	57.20	-$63.06M	-$0.69	N/A

95.0% of Enanta Pharmaceuticals shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 11.5% of Enanta Pharmaceuticals shares are held by insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Enanta Pharmaceuticals presently has a consensus target price of $19.00, suggesting a potential upside of 57.02%. Milestone Pharmaceuticals has a consensus target price of $6.40, suggesting a potential upside of 798.75%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Enanta Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enanta Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

Milestone Pharmaceuticals beats Enanta Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Turn Therapeutics?

Milestone Pharmaceuticals (NASDAQ:MIST) and Turn Therapeutics (NASDAQ:TTRX) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Turn Therapeutics has lower revenue, but higher earnings than Milestone Pharmaceuticals. Turn Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	57.20	-$63.06M	-$0.69	N/A
Turn Therapeutics	N/A	N/A	-$3.19M	-$0.29	N/A

Milestone Pharmaceuticals presently has a consensus price target of $6.40, indicating a potential upside of 798.75%. Turn Therapeutics has a consensus price target of $9.00, indicating a potential downside of 20.98%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than Turn Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Turn Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.50

Turn Therapeutics' return on equity of -230.84% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Turn Therapeutics	N/A	-230.84%	-53.19%

In the previous week, Turn Therapeutics had 2 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 2 mentions for Turn Therapeutics and 0 mentions for Milestone Pharmaceuticals. Turn Therapeutics' average media sentiment score of 0.27 beat Milestone Pharmaceuticals' score of 0.00 indicating that Turn Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Neutral
Turn Therapeutics	Neutral

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Milestone Pharmaceuticals and Turn Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Adherex Technologies?

Milestone Pharmaceuticals (NASDAQ:MIST) and Adherex Technologies (NASDAQ:FENC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Milestone Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Adherex Technologies has a beta of 1.23, meaning that its share price is 23% more volatile than the broader market.

Milestone Pharmaceuticals presently has a consensus target price of $6.40, suggesting a potential upside of 798.75%. Adherex Technologies has a consensus target price of $17.00, suggesting a potential upside of 59.92%. Given Milestone Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Milestone Pharmaceuticals is more favorable than Adherex Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Adherex Technologies	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Adherex Technologies has higher revenue and earnings than Milestone Pharmaceuticals. Adherex Technologies is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	57.20	-$63.06M	-$0.69	N/A
Adherex Technologies	$59.22M	6.31	-$9.74M	-$0.13	N/A

86.2% of Milestone Pharmaceuticals shares are held by institutional investors. Comparatively, 55.5% of Adherex Technologies shares are held by institutional investors. 5.0% of Milestone Pharmaceuticals shares are held by insiders. Comparatively, 10.7% of Adherex Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Milestone Pharmaceuticals has a net margin of 0.00% compared to Adherex Technologies' net margin of -6.09%. Adherex Technologies' return on equity of -5.71% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Adherex Technologies	-6.09%	-5.71%	-2.37%

In the previous week, Milestone Pharmaceuticals' average media sentiment score of 0.00 equaled Adherex Technologies'average media sentiment score.

Company	Overall Sentiment
Milestone Pharmaceuticals	Neutral
Adherex Technologies	Neutral

Summary

Milestone Pharmaceuticals and Adherex Technologies tied by winning 7 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Relmada Therapeutics (NASDAQ:RLMD) and Milestone Pharmaceuticals (NASDAQ:MIST) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

45.2% of Relmada Therapeutics shares are held by institutional investors. Comparatively, 86.2% of Milestone Pharmaceuticals shares are held by institutional investors. 14.5% of Relmada Therapeutics shares are held by company insiders. Comparatively, 5.0% of Milestone Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Relmada Therapeutics' return on equity of -47.52% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Relmada Therapeutics	N/A	-47.52%	-43.97%
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%

In the previous week, Relmada Therapeutics had 4 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 4 mentions for Relmada Therapeutics and 0 mentions for Milestone Pharmaceuticals. Relmada Therapeutics' average media sentiment score of 0.40 beat Milestone Pharmaceuticals' score of 0.00 indicating that Relmada Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Relmada Therapeutics	Neutral
Milestone Pharmaceuticals	Neutral

Relmada Therapeutics has a beta of 0.51, indicating that its stock price is 49% less volatile than the broader market. Comparatively, Milestone Pharmaceuticals has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market.

Relmada Therapeutics currently has a consensus target price of $12.00, indicating a potential upside of 278.55%. Milestone Pharmaceuticals has a consensus target price of $6.40, indicating a potential upside of 798.75%. Given Milestone Pharmaceuticals' higher possible upside, analysts plainly believe Milestone Pharmaceuticals is more favorable than Relmada Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Relmada Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.75
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71

Relmada Therapeutics has higher earnings, but lower revenue than Milestone Pharmaceuticals. Relmada Therapeutics is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Relmada Therapeutics	N/A	N/A	-$57.38M	-$0.90	N/A
Milestone Pharmaceuticals	$1.55M	57.20	-$63.06M	-$0.69	N/A

Summary

Relmada Therapeutics beats Milestone Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

How does Milestone Pharmaceuticals compare to Aurora Cannabis?

Milestone Pharmaceuticals (NASDAQ:MIST) and Aurora Cannabis (NASDAQ:ACB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, profitability, risk, valuation, earnings, analyst recommendations and media sentiment.

In the previous week, Aurora Cannabis had 22 more articles in the media than Milestone Pharmaceuticals. MarketBeat recorded 22 mentions for Aurora Cannabis and 0 mentions for Milestone Pharmaceuticals. Aurora Cannabis' average media sentiment score of 0.17 beat Milestone Pharmaceuticals' score of 0.00 indicating that Aurora Cannabis is being referred to more favorably in the news media.

Company	Overall Sentiment
Milestone Pharmaceuticals	Neutral
Aurora Cannabis	Neutral

Milestone Pharmaceuticals has a net margin of 0.00% compared to Aurora Cannabis' net margin of -32.26%. Aurora Cannabis' return on equity of 4.37% beat Milestone Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-288.33%	-58.27%
Aurora Cannabis	-32.26%	4.37%	3.45%

Milestone Pharmaceuticals has higher earnings, but lower revenue than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Milestone Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55M	57.20	-$63.06M	-$0.69	N/A
Aurora Cannabis	$314.07M	0.93	-$88.13M	-$1.41	N/A

Milestone Pharmaceuticals has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market. Comparatively, Aurora Cannabis has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Milestone Pharmaceuticals currently has a consensus price target of $6.40, indicating a potential upside of 798.75%. Given Milestone Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Milestone Pharmaceuticals is more favorable than Aurora Cannabis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Aurora Cannabis	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. Comparatively, 47.6% of Aurora Cannabis shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by insiders. Comparatively, 0.0% of Aurora Cannabis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Milestone Pharmaceuticals beats Aurora Cannabis on 12 of the 17 factors compared between the two stocks.

Get Milestone Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MIST and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MIST vs. The Competition

Export

Metric	Milestone Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$94.62M	$12.36B	$7.20B	$13.28B
Dividend Yield	N/A	2.65%	2.53%	16.36%
P/E Ratio	-1.10	795.16	274.48	26.17
Price / Sales	40.38	834.83	585.26	80.91
Price / Cash	N/A	86.17	76.82	53.72
Price / Book	1.95	10.71	11.21	6.34
Net Income	-$63.06M	$2.84B	$3.50B	$381.90M
7 Day Performance	-6.14%	-0.99%	-0.85%	-1.38%
1 Month Performance	-28.97%	-5.86%	-5.44%	-4.30%
1 Year Performance	-63.64%	-5.32%	4.34%	-0.35%

Milestone Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MIST Milestone Pharmaceuticals	1.8203 of 5 stars	$0.76 +6.7%	$6.40 +742.1%	-64.4%	$94.62M	$2.34M	N/A	38	News Coverage
ENTA Enanta Pharmaceuticals	1.9209 of 5 stars	$12.54 -0.5%	$19.00 +51.5%	+7.1%	$369.80M	$65.32M	N/A	120
TTRX Turn Therapeutics	2.0131 of 5 stars	$12.35 -0.1%	$9.00 -27.1%	N/A	$368.80M	N/A	N/A	2	News Coverage Short Interest Increase Gap Up
FENC Adherex Technologies	3.9756 of 5 stars	$10.44 -1.7%	$17.00 +62.8%	+15.3%	$367.40M	$59.22M	N/A	35
RLMD Relmada Therapeutics	2.4909 of 5 stars	$3.43 -1.6%	$12.00 +250.4%	+48.8%	$367.37M	N/A	N/A	17

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MIST) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. ENTA, TTRX, FENC, RLMD, and ACB

How does Milestone Pharmaceuticals compare to Enanta Pharmaceuticals?

Summary

How does Milestone Pharmaceuticals compare to Turn Therapeutics?

Summary

How does Milestone Pharmaceuticals compare to Adherex Technologies?

Summary

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Summary

How does Milestone Pharmaceuticals compare to Aurora Cannabis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Milestone Pharmaceuticals (MIST) Competitors

MIST vs. ENTA, TTRX, FENC, RLMD, and ACB

How does Milestone Pharmaceuticals compare to Enanta Pharmaceuticals?

Does the media favor ENTA or MIST?

Which has more risk and volatility, ENTA or MIST?

Is ENTA or MIST more profitable?

Which has stronger earnings and valuation, ENTA or MIST?

Do insiders and institutionals hold more shares of ENTA or MIST?

Do analysts prefer ENTA or MIST?

Summary

How does Milestone Pharmaceuticals compare to Turn Therapeutics?

Which has stronger valuation & earnings, MIST or TTRX?

Do analysts recommend MIST or TTRX?

Is MIST or TTRX more profitable?

Does the media refer more to MIST or TTRX?

Do insiders and institutionals have more ownership in MIST or TTRX?

Summary

How does Milestone Pharmaceuticals compare to Adherex Technologies?

Which has more risk & volatility, MIST or FENC?

Do analysts rate MIST or FENC?

Which has better valuation and earnings, MIST or FENC?

Do institutionals and insiders hold more shares of MIST or FENC?

Is MIST or FENC more profitable?

Does the media refer more to MIST or FENC?

Summary

How does Milestone Pharmaceuticals compare to Relmada Therapeutics?

Do institutionals and insiders have more ownership in RLMD or MIST?

Is RLMD or MIST more profitable?

Does the media prefer RLMD or MIST?

Which has more volatility and risk, RLMD or MIST?

Do analysts recommend RLMD or MIST?

Which has preferable valuation and earnings, RLMD or MIST?

Summary

How does Milestone Pharmaceuticals compare to Aurora Cannabis?

Does the media refer more to MIST or ACB?

Is MIST or ACB more profitable?

Which has higher valuation and earnings, MIST or ACB?

Which has more volatility & risk, MIST or ACB?

Do analysts recommend MIST or ACB?

Do institutionals & insiders believe in MIST or ACB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MIST vs. The Competition

Milestone Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools